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 ABSTRACT 
OBJECTIVE: The objective of this systematic review is to determine whether or not liraglutide 
is safe and effective as a monotherapy for the treatment of obesity in type 2 diabetics and healthy 
individuals. 
STUDY DESIGN: Review of three English language, primary, double-blind, randomized, 
controlled trial studies from 2004, 2007, and 2009 
DATA SOURCES: Randomized, double blind, placebo-controlled trials comparing liraglutide to 
placebo, Orlistat, or Metformin were found using Ovid, MEDLINE, and COCHRANE databases 
OUTCOMES MEASURED: Each of the three trials involved varying doses of liraglutide. The 
primary outcome measured in all three studies was reduction in bodyweight.  Feinglos et al. 
monitored patient’s weight on weeks -4, 0, 1, 4, 8, 12, and a follow-up visit.  Astrup et al. 
recorded weight loss weekly for the first 4 weeks, and then every other week for the rest of the 
20 week trial.  Volsboll et al. weighed patients at baseline and then at the completion of the 14 
week treatment.  Adverse events were determined as those participants that experienced 
gastrointestinal upset and those that did not. 
RESULTS:   All three RCT’s included in this review found that liraglutide helps with weight 
loss in both type 2 diabetics and nondiabetic obese individuals.  While Astrup et al. and Vilsboll 
et al. proved the highest dosages of liraglutide were superior to Orlistat and placebo for weight 
loss, Feinglos et al. showed comparable results of weight reduction when comparing liraglutide 
to Metformin.  In all three trials, the most common adverse events were gastrointestinal side 
effects, including nausea, vomiting, and diarrhea. 
CONCLUSIONS: The results of the Astrup et al. and Vilsboll et al. show that use of liraglutide 
as a monotherapy for type 2 diabetics and nondiabetics is effective for treating obesity.   These 
studies demonstrated that dosages above 1.90mg were most successful for weight reduction.  
However, dosages of liraglutide below 0.75mg, as was used in Feinglos’ study, are not as 
effective. 
KEY WORDS:  Obesity, weight loss, liraglutide, type 2 diabetics 
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INTRODUCTION 
 Obesity is a substantial public-health crisis in the United States, and its prevalence is 
increasing in developing nations worldwide.  Globally, at least 300 million people are clinically 
obese.  In America, 60% of people are overweight and nearly 30% are obese.  The annual cost of 
managing obesity in the US is ~$117 billion, of which, ~$52 billion are direct costs of healthcare 
and nearly $33 billion is spent annually on weight-loss products and services.
5
 
Excessive caloric intake and inadequate caloric expenditure lead to obesity and 
predispose individuals to type 2 diabetes.  Being overweight puts added pressure on the body's 
ability to properly control blood sugar using insulin and therefore makes it much more likely for 
a person to develop diabetes.7  Additionally, obesity and type 2 DM are risk factors for 
cardiovascular disease, the leading cause of death worldwide and a major concern for Physician 
assistants working in any field.
4
  Healthcare providers have been searching for new ways to 
decrease obesity rates, improve diabetic care, and subsequently improve quality of life for 
Americans. 
There are few safe and effective drugs currently available for the treatment of obesity.  
Healthcare providers suggest Xenical (Orlistat), Phentermine (Apidex-P), or the over-the-counter 
diet pill Alli ® as a few options to facilitate weight loss in the overweight and obese. While these 
therapies may provide modest weight loss, researchers are looking for more safe and effective 
options for weight reduction.  
Diabetics, unfortunately, face an added concern as tight glucose control, while important 
for preventing complications of the disease, often leads to weight gain.  Metformin, a commonly  
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used therapeutic agent for diabetes, lowers blood glucose without inducing weight gain making it 
one of the more successful treatment options for type 2 diabetics.
2
  However, Metformin is not 
effective for weight reduction. 
Liraglutide, a drug initially used for glycemic control in type 2 diabetics, is a glucagon-
like peptide-1 (GLP-1) analogue with structural similarity to the human GLP-1.  GLP-1 is a gut-
derived incretin hormone that suppresses appetite and delays gastric emptying.  Obese 
individuals and type 2 diabetics have been shown to have an attenuated GLP-1 response to 
meals.
2
  Researchers proposed that a once daily subcutaneous injection of liraglutide, in 
combination with a low-fat diet and physical activity, would cause weight reduction and glucose 
control offering an appealing option for both type 2 diabetes and obesity.    
OBJECTIVE 
The objective of this systematic review is to determine whether or not liraglutide is safe 
and effective as a monotherapy for the treatment of obesity in type 2 diabetics and healthy 
individuals.   
METHODS 
 Criteria used for the selection of studies included obese patients >18yo with or without 
type 2 diabetes.  The intervention assessed in these studies was varying doses of Liraglutide in 
comparison to Orlistat or placebo in non-diabetic patients, and Metformin or placebo in type 2 
diabetics.  Outcomes studied were dose-dependent reductions in body weight.  Adverse reactions  
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such as severity of gastrointestinal discomfort, including nausea, vomiting, and diarrhea were 
also taken into account. 
 The search for articles was performed using OVID, MEDLINE, and Cochrane.   Key 
words used in the search included “obesity”, “weight loss”, “type 2 diabetics”, and “liraglutide”. 
Articles were selected based on the importance of outcomes to the patient (Patient Oriented 
Evidence that Matters, or POEMS).  The three studies chosen were randomized, double-blind 
control trials of liraglutide in comparison to Orlistat, Metformin, or placebo.  All articles were 
published in English and all were published in peer-reviewed journals from 2004 to 2009.  
Inclusion criteria was based on studies that used liraglutide as a monotherapy, were randomized, 
controlled, and were based on patient oriented outcomes.  Exclusion criteria involved studies that 
focused on combination treatment with liraglutide.  Statistics reported included p-values, 
confidence intervals (CI), relative risk increase (RRI), absolute risk increase (ARI), and numbers 
needed to harm (NNH). 
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Table of demographics of included studies (Table 1)     
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Astrup, 
2009 
(1) 
Randomized, 
double-blind, 
placebo-
controlled 20-
week trial 
564 18-65 Aged 18-65 
BMI 30-
40kg/m
2
 
Stable 
bodywt. (<5% 
change in 
previous 3 
months) 
-FPG < 
7mmol/L  
Type 1 or 2 diabetes 
Obesity induced by 
drug tx 
Use of wt-lowering 
pharmacotherapy or 
participation in a 
clinical wt. control 
study in past 3 mos. 
Previous surgical 
obesity tx 
Major medical 
conditions 
74 -Liraglutide 
1.2, 1.8, 2.4, 
or 3.0mg SQ 
QID 
Feinglos, 
2004 
(2) 
12 wk, 
randomized, 
multicentre, 
double-blind, 
parallel-group, 
double-
dummy study 
210 18-75 Aged 18-75 
Type 2 
diabetics 
(BMI 27-42 
kg/m
2
) who 
received at 
least 3 months 
of previous tx 
with an OAD 
monotherapy 
-HbA1c <10% 
High levels of anti-
GAD 
ALT (>2x upper 
normal range) 
Serum Cr (> 
133mmol/L or 
1.5mg/dL for males 
and >124mmol.l or 
1.4mg/dL for females) 
Unstable cardiac dz, 
uncontrolled HTN, 
proliferative 
retinopathy, 
autonomic neuropathy, 
or recurrent severe 
hypoglycemia 
Use of drugs which 
could interfere with 
glucose levels or 
bodywt. 
C/I to metformin use, 
tx with 
thiazolidinediones, or 
chronic use of insulin 
(>7days) w/in past 3 
mos 
31 -Liraglutide 
0.045, 0.225, 
0.45, 0.5, and 
0.75mg 
Vilsboll, 
2007 
(3) 
Double-blind, 
randomized, 
and placebo-
controlled trial 
165 >18 >18yo w/ type 
2 diabetes and 
A1c >7.5 and 
<10.0% 
FPG 7-13 
mmol/L 
Previous 
therapy d/c 
FPG > 15mmol/L 
during the study 
25 Liraglutide 
0.65, 1.25, or 
1.90mg SQ 
QD 
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OUTCOMES MEASURED 
The primary outcome measured in all three studies was reduction in bodyweight.  In 
Feinglos et. al’s 12 week trail they measured participants’ bodyweight, taking an average of three 
consecutive morning fasting measurements, at each visit.  This was done on weeks -4, 0, 1, 4, 8, 
12 and a follow-up visit.
2
  In Astrup et. al’s study bodyweight was taken weekly for the first 4 
weeks of the 20 week, and thereafter participants were assessed about once every 2 weeks. 
Standardized assessments of waist circumference were made on initial visit and every 4 weeks 
thereafter.
1 
 Vilsboll et. al conducted a study in which total bodyweight reduction after the 14 
week trial was the measured outcome.
6
 
All three studies also assessed adverse reactions, as liraglutide has been known to most 
notably affect the gastrointestinal tract.  In each trial, the proportion of subjects with treatment 
emergent adverse events (TEAEs) was recorded for each treatment group. 
RESULTS 
 The three randomized, controlled trials presented in this review involved data presented 
as an intention to treat analysis.  All participants were randomly selected to receive treatment to 
reduce bodyweight.  The Astrup et al study compared liraglutide to placebo and Orlistat in obese, 
non-diabetic patients over 12 weeks of treatment.  Participants received 1.2, 1.8, 2.4, or 3.0mg of 
liraglutide once a day by subcutaneous injection; placebo once a day by subcutaneous injection; 
or Orlistat 120mg three times a day orally.
1
  The other two studies focused on obese, type 2 
diabetic patients.  Feinglos et al compared five liraglutide doses, 0.045, 0.225, 0.45, 0.6, and  
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0.75mg taken subcutaneously once a day to Metformin 1000mg taken orally twice a day over a 
12 week trail.
2
  Visboll et al used liraglutide once daily subcutaneous injections at dosages of 
0.65, 1.25, or 1.90mg compared to placebo once daily injections in their 14 week trial.
6
   
Inclusion criteria for all three studies were similar, as seen in Table 1.   
 In the Astrup study 564 participants were randomly assigned and 472 (84%) completed 
the trial.  Three individuals treated with liraglutide (1.2, 2.4, and 3.0mg) were excluded due to 
missing post-baseline weight data.  Major protocol deviations included non-compliance with 
eligibility criteria (n=3), assessments at week 20 outside visit window (n=12), treatment 
compliance issues (n=7), and trial drug dispensing errors (n=1); these people were excluded.
1
  In 
Feinglos’ trial 210 subjects were randomized, while 179 (85%) participants completed the study.  
This reduction due to withdrawal because of adverse events (n =7), ineffective therapy (n=9), 
non-compliance with protocols (n=5), and other reasons (n=10).
2
  Lastly, Visboll’s study 
included the least amount of randomized participants, numbering 165.  Twenty-five were 
withdrawn due to adverse events (n=7), noncompliance (n=2), ineffective therapy (n=14), other 
(n=2).
6
   
 All three studies presented the primary outcome in continuous form that could not be 
converted to dichotomous data.  They focused on mean reduction in body weight from baseline.  
In the Astrup study, those participants receiving the varying liraglutide dosage, all showed 
greater decreases in bodyweight after the 20week trial when compared to control groups.  Mean 
changes in bodyweight were recorded as 6.7, 7.1, 7.9kg weight loss in the 1.2, 1.8, and 2.4mg 
dosage groups respectively.  The largest average weight reduction was seen in 3.0mg dose group 
losing 9.1kg compared to the 4.1kg loss in those on placebo and 5.5kg loss in those participants  
         Sheeran: Liraglutide and Obesity 7 
 
on Orlistat.  Mean changes in bodyweight with liraglutide was significantly greater at all dosage 
levels when compared to placebo or Orlistat in obese non-diabetics.
1
 
 The Feinglos study compared percentage change in bodyweight throughout the trial.  
After 12 weeks, the metformin group had a slight weight loss of -0.61% (p= 0.124 relative to 
baseline), whereas the five liraglutide groups had a weight loss ranging from -0.05% (0.45mg, 
p=0.825 relative to baseline) to -1.87% (0.225mg, p=0.006 relative to baseline).  The percentage 
of weight change in the five liraglutide dosage groups was not significantly different from the 
metformin therapy.
2
 
 In Volsboll’s study bodyweight decreased in all treatment groups, 1.90mg, 1.25mg, 
0.65mg, and placebo.  Maximum estimated loss of 2.99kg was noted in the 1.90mg liraglutide 
group.  The difference compared with placebo was significant only for the 1.90mg group            
(-1.21kg [95%CI -2.36 to -0.06] p=0.0390).
6
 
 In each of the studies participants experienced adverse gastrointestinal effects.  This data 
was reported as the number of participants that experienced constipation, diarrhea, nausea or 
vomiting.   This information was presented in dichotomous form as those that experienced GI 
adverse events and those in the study that did not.  Through this comparison the “control event 
rate” (CER) was determine as those receiving placebo who experienced GI disorders and the 
“experimental event rate” (EER) as those administered liraglutide who had GI adverse events.   
Using these numbers the relative risk increase (RRI) and the absolute risk increase (ARI) were 
calculated.  The numbers need to harm (NNH) was then computed to find out how many people  
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would have to be treated with liraglutide in order for one person to experience adverse events.  
The calculated analysis of outcomes and numbers needed to harm can be seen in Table 2. 
Table 2.  Analysis of Outcomes and NNH in Percentage of Patients Experiencing Adverse 
GI Effects with Liraglutide vs. Placebo 
Study # completed 
study 
CER EER RRI ARI NNH 
Astrup 564 30.6% 71.0% 1.32% 40.4% 2 
Feinglos 179 8.8% 6.3% -28% -2.5% -40 
Vilsboll 140 23% 37% 61% 14% 7 
 
DISCUSSION 
 The three studies addressed in this paper show, at higher dosages, liraglutide is effective 
in bodyweight reduction for obese individuals with and without type 2 diabetes.  Additionally, 
the studies show other benefits for diabetics including tight glycemic control and lowering of 
HbA1c.  However, concerning adverse events have been found that are not mentioned in any of 
the three studies.  Black box warnings state that liraglutide has been associated with an increased 
risk of thyroid C-cell focal hyperplasia and C-cell tumor in rodent studies; however, it has 
unknown relevance in humans.  Another safety concern is a possible increased risk of 
pancreatitis attributable to drugs that act through the GLP-1 pathway.
3
  Considering this, the 
FDA granted approval of liraglutide on the basis of careful consideration of the drug's benefits, 
weighed against several complex safety-related concern.   
 The studies chosen for this review did have certain limitations, as the reduction of 
bodyweight was based on use of randomly selected therapy as well as proper diet and exercise.  
This may have affected outcomes as varying amounts of exercise and dietary control were  
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naturally present among participants.  Also, concealing which therapy patients received may 
have caused blinding to be compromised.  The trials were masked for liraglutide and placebo as 
both were given as once a day subcutaneous injections.  However, the individuals in Astrup’s 
and Feinglos’ studies were given open label Orlistat and Metformin, respectively, thus 
introducing a potential for bias.
1 
 
CONCLUSION 
 The studies reviewed demonstrate that at higher dosages, liraglutide offers a safe and 
effective option for the treatment of obesity for individuals with and without type 2 diabetes.  As 
proved by Astrup’s 20 week study, administration of once daily liraglutide 2.4mg and 3.0mg 
subcutaneous leads to significant weight loss and in turn, reduction in rates of prediabetes.
1
  
Furthermore, in Vilsboll’s study in spite of improved in glycemic control, which is usually 
associated with weight gain in type 2 diabetics, liraglutide offered a dose-dependent decrease in 
bodyweight.
6 
 While Feinglos’ study showed treatment with liraglutide at doses of 0.045-0.75mg 
resulted in reductions in weight, these findings were comparable with the metformin control 
group.
2 
 This leads to the conclusion that levels of Liraglutide above 0.75mg will prove effective 
in weight reduction.  Further testing starting at higher dosages should be performed. 
 Long-term effects of liraglutide on bodyweight need to be addressed.  While liraglutide 
led to weight loss and improved several factors associated with cardiovascular events during 
these trials, the long-term risk-benefit and weight maintenance capabilities, still need to be 
established.
1 
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